Drugs / Adriamicine
last change Jun 2010 re-read 2 minutes ago

Adriamicine

Developed for
plasma cell myeloma
Investigated by
PETHEMA Foundation

Trials 1 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT00652041 Jan 2007 → Jan 2010 plasma cell myeloma PETHEMA Foundation Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Adriamicine “Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or...” NCT00652041
Route Intravenous “Adriamicine, 40 mg/m2 IV day 1” NCT00652041